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Abstract
Hydrocarbon stapling can restore bioactive, α-helical structure to natural peptides, yielding 
research tools and prototype therapeutics to dissect and target protein interactions. Here, we 
explore the capacity of peptide stapling to generate high fidelity, protease-resistant mimics of 
antigenic structures for vaccine development. HIV-1 has been refractory to vaccine technologies 
thus far, although select human antibodies can broadly neutralize HIV-1 by targeting sequences of 
the gp41 juxtamembrane fusion apparatus. To develop candidate HIV-1 immunogens, we 
generated and characterized stabilized α-helices of the membrane proximal external region (SAH-
MPER) of gp41. SAH-MPER peptides were remarkably protease-resistant and bound to the 
broadly neutralizing 4E10 and 10E8 antibodies with high affinity, recapitulating the structure of 
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the MPER epitope when differentially engaged by the two anti-HIV Fabs. Thus, stapled peptides 
may provide a new opportunity to develop chemically-stabilized antigens for vaccination.
INTRODUCTION
Antibodies neutralize pathogens by recognizing discrete and distinguishing peptidic motifs. 
By presenting primary, secondary, and tertiary structures to the host immune system, 
vaccines have revolutionized our capacity to prevent human infection. Nevertheless, some 
targets, such as human immunodeficiency virus type 1 (HIV-1), have been refractory to 
vaccine development. To achieve sterilizing HIV-1 immunity, an effective vaccine must 
elicit broadly neutralizing antibodies that intercept the virus prior to immune cell 
penetrance1. Upon interaction of the HIV-1 envelope (Env) glycoprotein with host receptors, 
the Env viral fusion protein undergoes a series of conformational changes that are essential 
to penetrating the plasma membrane and fusing the viral and host membranes. Three copies 
of the HIV-1 envelope glycoproteins gp120 and gp41, which are non-covalently associated, 
form the Env trimer2. Once gp120 binds to CD43 and co-receptor4 on the host cell 
membrane, gp41 transforms from its metastable native state into a fusogenic six-helix 
bundle5,6 that conjoins viral and host cell membranes, enabling viral particle uptake. The 
regions of gp41 involved in this structural reorganization are the N-terminal heptad repeat 
(HR1) found just downstream of the fusion peptide and the C-terminal heptad repeat (HR2) 
that is close to the transmembrane region. The membrane-proximal external region7 
(MPER) is downstream from HR2 and contains antigenic sequences recognized by several 
broadly neutralizing human antibodies, including 2F57, Z13e18, 4E109, and 10E810.
Structural studies have identified critical motifs in gp41 that engage broadly neutralizing 
antibodies10–17. The crystal structure of 4E10 fragment antigen-binding (Fab) in complex 
with a 13-residue portion of the MPER (amino acids 671-683) demonstrated that this peptide 
epitope adopts an α-helical conformation. Residues W672-D674 are configured as a short 
310 helix that directs the N-terminus out of the binding site18 and the interaction surface is 
comprised of key residues W672, F673, I675, and T67612. Analysis of a longer 22-residue 
MPER peptide (amino acids 662-683) in a lipid context, using a combination of nuclear 
magnetic resonance (NMR) and electron paramagnetic resonance (EPR) spectroscopy, 
revealed a unique L-shaped structure, reflecting a bipartite α-helix segmented by a kink17. 
The 10E8 antibody also recognizes an extended MPER peptide (amino acids 656-683) in a 
helix-kink-helix conformation, with each αhelix oriented 100° relative to the other10. In 
contrast, 2F5 binds to its target MPER sequences in a largely extended conformation with a 
central β-turn16. Importantly, upstream α-helical HR2 sequences, the transmembrane 
domain, the trimeric nature of the viral spike, and the plasma membrane itself may provide 
an important structural context that constrains and thereby helps define the neutralization-
competent antigenic structure(s) of the MPER19.
Diverse approaches have been applied to display the MPER domain for vaccine 
development, including computational design of epitope scaffolds20–24, MPER grafting25, 
use of chimeric viruses26, and immunizing with cells expressing the gp41 post-fusion 
complex27. Despite these efforts, non-neutralizing responses are the norm23–25. The 
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conformations and orientations of MPER sequences displayed on the surface of 
nanoparticles28, rhinovirus26, or human cells27 may be distinct from the pathologic epitope 
in vivo or elicit off-target immune responses to the scaffold itself. Peptidic approaches to 
MPER mimicry have also been unsuccessful to date, potentially due to limitations in peptide 
size, stability, and delivery, as documented for peptide vaccine studies in general29–31.
Introduction of non-covalent or covalent constraints to stabilize variably-structured MPER 
sequences of different length has enhanced binding to select broadly neutralizing antibodies, 
but did not necessarily elicit a broadly neutralizing response.32,33 These data suggest that 
perhaps an MPER motif of optimal size or structure in the appropriate context (such as the 
membrane environment) was not reproduced, or structural integrity was not maintained in 
vivo due to proteolysis. We have found for structured therapeutic peptides that non-
covalently constrained constructs are rapidly proteolyzed34, and covalently-constrained 
peptides bearing labile crosslinks (e.g. disulfides, amides) are also vulnerable. Indeed, the 
structural lability of the Env trimer itself was recently shown to be a critical factor in 
eliciting non-neutralizing anti-HIV-1 antibodies35. Although broadly neutralizing antibodies 
that target the HIV-1 envelope are among the most protective for preventing HIV-1 
transmission, the requisite set of immunogens to appropriately guide an effective immune 
response has been elusive to date36.
Two of the historically most broadly neutralizing monoclonal antibodies, 2F5 and 4E10, 
have been proposed to cross-react with self-antigens37–42, raising the specter of 
autoreactivity as an unwanted consequence of a potential MPER-based vaccine. To preclude 
autoreactivity, a normal immune response may not permit the emergence of MPER-directed 
neutralizing antibodies. Such concerns, however, have been mitigated by the recent 
discovery of 10E8, a potent and broadly neutralizing antibody that also engages a helical 
MPER, but without autoantigen recognition10, providing a compelling basis for revisiting an 
MPER-based vaccine strategy. Interestingly, a recent follow-up study demonstrated that 
10E8 retains weak affinity for lipid membranes and suggested a functional role for apical 
residues of its complementarity determining region (CDR)-H3 in membrane binding and 
viral neutralization43, as also observed for 2F521 and 4E1020. Taken together, these studies 
indicate that effective HIV-1 neutralization by MPER-specific antibodies mechanistically 
involves interactions with viral lipids16,20,21,43, yet structural delineation of the lipid binding 
site(s) on MPER antibodies is lacking. Ultimately, structured MPER peptides presented in a 
lipid context or MPER-based antigens designed to contain lipid recognition moieties may be 
ideally suited for vaccine development43.
Motivated by fresh insights into the conformation of MPER epitopes in the membrane 
context17 and in complex with potent and broadly neutralizing antibodies10, we sought to 
design stabilized α-helices of MPER domains (SAH-MPERs) that reflect the full-length 
domain, reinforcing both helical components of the helix-kink-helix structure. Our peptide 
stapling method has yielded remarkably protease-resistant α-helical peptides34, transforming 
tool reagents into prototype therapeutics with in vivo efficacy44–47. Importantly, the all-
hydrocarbon constraint is itself protease-resistant, differentiating this chemical approach 
from prior peptide-stabilization efforts and potentially rendering it well-suited for the 
development of structured antigens in general. Here, we demonstrate that SAH-MPER 
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peptides retain high affinity binding activity toward two broadly neutralizing anti-HIV-1 
antibodies, exhibit markedly enhanced protease resistance, and recapitulate the critical 
antibody recognition motif, as evidenced by crystal structures of the corresponding 4E10 
and 10E8 complexes.
RESULTS
Design and 4E10-binding Activity of SAH-MPER Peptides
To generate candidate HIV-1 immunogens with neutralization-competent structure, we 
sought to replicate the bipartite α-helical conformation of the full-length MPER domain 
(Fig. 1a). To independently stabilize the respective N- (662-671) and C- (675-683) terminal 
helices, which are separated by a flexible hinge region (672-674), we performed staple scans 
in each region of the MPER peptide. Pairs of (S)-2-(((9H-fluoren-9-
yl)methoxy)carbonylamino)-2-methyl-hept-6-enoic acids (abbreviated as S5 residues) were 
substituted at i, i+4 positions within the N-terminal region followed by ruthenium-catalyzed 
ring-closing metathesis (RCM) to generate six single-stapled peptides, termed SAH-
MPER(662-683) A through F (Fig. 1b, Supplementary Table 1). Within the C-terminal region, 
i, i+4 and i, i+3 substitutions were made in order to accommodate α- or 310-helical 
conformation, yielding thirteen single-stapled peptides, termed SAH-MPER(662-683) G-L (i, i
+4) and M-S (i, i+3) (Fig. 1c). Of note, i, i+3 hydrocarbon stapling of S5 residues required 
a prolonged reaction time at elevated temperature to achieve yields similar to the traditional 
i, i+4 reaction, consistent with pentane interference from the resultant crosslink that drapes 
over the N-terminal α-methyl group48.
We compared the binding activity of 4E10 antibody across our diversity of hydrocarbon-
stapled peptides by competitive enzyme-linked immunosorbent assay (ELISA), pitting the 
unmodified MPER peptide (amino acids 662-683) against FITC-labeled competitor 
constructs. Whereas the affinity-driving contacts of 4E10 are on the C-terminal half of the 
MPER peptide12, we chose to incorporate N-terminal MPER sequence into our designs to 
maximize their potential immunogenic surface. Among the N-terminal i, i+4 stapled 
constructs, all but the most C-terminal F staple was tolerated, consistent with this N-terminal 
portion of the MPER domain lying outside the core 4E10-binding region and staple 
encroachment on the kink region being disfavored (Fig. 1b). Among the C-terminal i, i+4 
and i, i+3 stapled constructs, only two constructs showed 4E10 binding activity. In each 
case, the favorable staple localized to the non-interacting helical surface and centered around 
the highly conserved L679-W680 motif. The C-terminal i, i+4 staple K conferred a 3-fold 
improvement in 4E10 binding activity, whereas the i, i+3 staple Q yielded a 60-fold 
enhancement (Fig. 1c). The exquisite sensitivity of 4E10-binding activity to staple location 
emphasizes the importance of staple scanning to identify insertion points that balance 
structural reinforcement and preservation of key residues and binding interfaces.
To reinforce both helical motifs that flank the kink and maximize protease resistance34, we 
sought to generate double-stapled peptides, combining the C-terminal i, i+3 Q staple with 
those N-terminal staple positions that yielded similar or improved 4E10 binding activity (A–
E). However, the designed (i, i+4), (i, i+3) MPER constructs either failed to metathesize or 
resulted in minimal yield even after prolonged reaction at elevated temperatures, consistent 
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with the requirement for relatively extreme conditions to accomplish single i, i+3 stapling 
with S5. These results compelled us to determine which alternative non-natural olefin-
bearing amino acids would enable i, i+3 stapling to proceed as smoothly as single and 
double i, i+4 stapling with S534.
Optimization of i, i+3 Stapling for SAH-MPER Design
We tested the reactivity of an alternative stapling amino acid pair in order to optimize i, i+3 
stapling for SAH-MPER synthesis. For a simplified peptide template, we used the 
previously described 4E10-binding epitope that corresponds to the C-terminal half of the 
MPER domain with an appended trio of lysines to enhance solubility18 (hereafter referred to 
as MPER(671-683KKK)). S5 residues were installed at positions 678 and 681 and the resin-
bound peptide exposed to ruthenium-catalyzed RCM for 2 h at room temperature, with no 
observed metathesis (data not shown). The reaction conditions were then escalated to an 18 
h incubation at 84°C (reflux in dichloroethane) and only 20% conversion was achieved, as 
demonstrated by an overlay of the high performance liquid chromatography (HPLC) traces 
of starting material and reaction product (Fig. 2a). We reasoned that shortening the alkenyl 
side chain of one of the amino acids from 5 to 3 carbons and inverting the more N-terminal 
stereocenter would mitigate steric hindrance and orient the olefins toward each other. 
Therefore, we installed an S5 residue at position 681 and an R3 residue, (R)-2-(((9H-
fluoren-9-yl)methoxy)carbonylamino)-2-methyl-pent-4-enoic acid, at position 678. 
Remarkably, we achieved almost complete conversion of the starting material into 
metathesized product with only 2 h incubation at room temperature, matching the synthetic 
efficiency of i, i+4 stapling with two S5 residues (Fig. 2b). Consistent with the enhanced 
4E10 binding affinity derived from S5-S5 stapling at the Q position of the full-length MPER 
peptide, R3-S5 stapling of the 671-683KKK construct at position Q (designated q to reflect 
the alternate staple composition) resulted in 5-fold improvement in competitive binding 
activity compared to the unmodified MPER(671-683KKK) peptide (Fig. 2c).
Crystal Structure of a Stapled MPER Peptide Bound to 4E10
We determined the crystal structure of the 4E10 Fab–SAH-MPER(671-683KKK)(q) complex 
at 2.9 Å resolution with one Fab–peptide complex per asymmetric unit (Fig. 3a, Table 1). 
With the exception of the C-terminal lysine side chains, all main chain and side chains of the 
stapled peptide residues could be modeled into the electron density map (Fig. 3b). The 
relatively weak electron density for the region of the 6-atom carbon staple, which replaced 
the side chains of W678 and Y681, could not distinguish between Z and E olefin isomers (or 
exclude the possibility of a stereoisomeric mixture), and was modeled in a Z conformation in 
this 2.9 Å structure. Density appears for most of the main chain of the flexible 
complementarity-determining region (CDR)-H3 loop (residues 99-100D, except W100(H) 
and G100A(H)) (Supplementary Fig. 1a)18. The complexes of 4E10 Fab with SAH-
MPER(671-683KKK)(q) and the original (unmodified) 4E10-epitope peptide (PDB 2FX7)18 
superimpose with a root-mean-square-deviation of 0.73 Å for the Cα atoms, and are overall 
very similar (Supplementary Fig. 1b). Superimposing the peptide regions revealed 
essentially identical Fab-binding interfaces, highlighting that the q staple reinforces the 
natural peptide-bound structure (Fig. 3c). Like the side chains of W678 and Y681, the 6-
carbon staple that replaces these natural residues does not contact the antibody due its 
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location on the solvent-exposed face of the helical peptide. Thus, hydrocarbon stapling 
effectively recapitulates the native antigenic epitope, with the structurally-reinforcing staple 
positioned away from, and thereby not perturbing, the critical binding interface.
Identification of a Phosphate Binding Site on 4E10
The MPER-specific antibodies 2F5 and 4E10 can also bind several phospholipid antigens39. 
The initial difference Fourier electron density map of our 4E10 Fab–SAH-
MPER(671-683KKK)(q) complex revealed roughly spherical electron density of approximately 
7σ located between S28H and S30H of the CDR-H1 loop (Fig. 4a, 4b). Both phosphate and 
chloride ions were present in the crystallization conditions (based on mother liquor 
conditions that contained sodium and potassium phosphate [0.1 M] and sodium chloride [0.2 
M]). When a chloride ion was refined into the extra density, residual positive electron 
density still remained in Fo-Fc maps. Thus, the spherical density was interpreted as a 
phosphate ion, which fits the density with a real space correlation coefficient of 0.96. 
Although the B-value for the phosphate ion is high (~110 Å2, Table 1) compared to the 
overall protein, it is nevertheless close to that of neighboring CDR-H1 residues (ca. 90 Å2 
for S28(H), 74 Å2 for F29(H) and 83 Å2 for S30(H); Fig. 4b). Elevated isotropic B-values 
were also observed for these CDR-H1 loop residues in the previous 4E10 Fab–SAH-
MPER(671-683KKK) structure in comparison to mean isotropic and Wilson B-values at the 
corresponding resolution18, and suggests increased structural flexibility. The 
superimposition of the phosphate-incorporated site with the same region in the 4E10 Fab–
native MPER(671-683KKK) complex (PDB entry 2FX7)18, which was crystallized from 
phosphate-free buffer, demonstrates torqueing of backbone amides and reorientation of the 
S28(H) hydroxyl toward the phosphate ion to promote favorable hydrogen bond interactions 
in the 4E10 Fab–SAH-MPER(671-683KKK)(q) structure (Fig. 4c). The presence of a 
phosphate binding site in the CDR-H1 loop region of 4E10 is consistent with antibody 
binding to anionic lipids at the membrane surface. Indeed, the orientation of SAH-
MPER(671-683KKK)(q) within the antigen binding site positions the C-terminal residues 
684-686, which are replaced here by lysines and would comprise the start of the gp41 
transmembrane segment, immediately adjacent to the identified phosphate-binding site (Fig. 
4a).
To our knowledge, we have detected this phosphate-binding site in the 4E10 combining 
region for the first time, as a PDB search of all available 4E10 structures did not reveal 
phosphate as a buffer component of prior crystallization conditions. A recent crystal 
structure of the 4E10 variable region (Fv) in an unliganded form49 shows sulfate ions near 
the CDR-H1 loop, but none of the ions are in the same position as observed here for the 
phosphate. In fact, a glycerol molecule is present in this position in one of the four Fv 
molecules in the asymmetric unit. Whereas sulfate and phosphate ions are similar, and can 
occupy the same binding site in a protein, the peptide-free structure of 4E1049 has its CDR-
H1 and CDR-H3 loops drastically perturbed compared to the peptide-bound form18. In the 
unliganded structure, the CDR-H3 occupies the peptide binding site but is also involved in 
extensive packing interactions with symmetry-related mates. It is also noteworthy that the 
acidic pH of 4.6 and the high salt concentration (0.4–0.8 M Li2SO4) in the crystals could 
impact the conformation. To avoid exposure of the hydrophobic residues in the combining 
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site, which otherwise interacts with the MPER, the CDR-H3 loop forms extensive packing 
interactions with symmetry-related mates and residues of the peptide binding-site. Thus, the 
disposition of the phosphate ion reported here in the liganded structure in the CDR-H1 of 
4E10 could indeed reflect a 4E10 membrane-binding interface. That said, we do not exclude 
participation of the hydrophobic CDR-H3 in membrane lipid interactions, as reported for 
2F516,21, 4E1020, and 10E843.
Crystal Structure of 4E10 and a SAH-MPER Phosphopeptide
To probe the potential role of phosphate-engagement as a 4E10 binding determinant at the 
membrane, we generated a modified SAH-MPER(671-683KKK)(q) peptide containing a 
tethered phosphate moiety. Based on the predicted 5.5 Å distance between the K683 side-
chain amine and phosphate group (Fig. 4a), we modeled in a phosphoserine (pSer) group 
and determined that it could be appropriately linked to the peptide backbone by a 
diaminobutanoic acid and glycine (Dab683-Gly) spacer (Fig. 5a). We then synthesized 
SAH-MPER(671-683KKK)(q) containing the Dab-Gly-pSer tether at the 683 position or, as a 
negative control, at the 685 position, which would orient pSer away from the binding 
interface (Supplementary Fig. 2a). Competitive 4E10 binding analysis revealed a slight 
improvement in binding affinity upon incorporation of a phosphate moiety at position 683, 
whereas installing the equivalent derivatization at position 685 actually reduced binding 
activity (Supplementary Fig. 2b).
To confirm that the installed phosphate moiety at position 683 interacted with the defined 
phosphate-binding site at the 4E10 interface, we undertook structural analysis of the 4E10 
Fab bound to phosphate-derivatized SAH-MPER(671-683KKK)(q)pSer peptide containing the 
Dab-Gly spacer. The structure of the complex was determined at 2.68 Å resolution from a 
crystal grown in phosphate-free mother liquor (Fig. 5b). The initial difference Fourier map 
shows unambiguous positive electron density for the covalently-linked staple, which fit the 
electron density with a real space correlation coefficient of 0.98 and an isotropic B-value of 
49 Å2, in good agreement with the Wilson plot and mean isotropic B values (Table 1; 
Supplementary Fig. 3a, 3b). In contrast, the initial positive Fo-Fc (3σ level) and the 2Fo-Fc 
(1σ level) maps show incomplete electron density for the central portion of the Dab-Gly 
linker (Supplementary Fig. 4a). However, the final 2Fo-Fc density at the Dab level 
(Supplementary Fig. 4b) improved after refinement compared with the density for the SAH-
MPER(671-683KKK)(q) K683 (Fig. 4b) or with the density for the same lysine in the 1.76 Å 
structure of native MPER(671-683KKK) in complex with 4E10 (PDB entry 2FX7)18, where 
density was observed only for the main chain. With the exception of two atoms (OZ1 and 
N6), all of the atoms of the Dab-Gly-pSer are located inside the 2Fo-Fc electron density map 
at the 0.8σ level (Supplementary Fig. 4c). Therefore, the strong density (5σ level in the 
initial Fo-Fc map) for the phosphate moiety and the improved density at the Dab level, 
combined with the absence of phosphate in the mother liquor, indicate that the Dab-Gly-
pSer tether at position 683 extends into the phosphate-binding site (Fig. 5b, 5c and 
Supplementary Fig. 4d). However, for the linker atoms that connect the peptide backbone to 
the phosphate moiety, reduced density for the eight-atom linker and a high isotropic B-value 
of approximately 112 Å2 (ca. 105 Å2 for the whole Dab-Gly-pSer residue, Table 1) is 
observed, indicative of its flexibility. The 4E10 Fab complexes with SAH-
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MPER(671-683KKK)(q)pSer and SAH-MPER(671-683KKK)(q) are otherwise very similar with 
only 0.23 Å r.m.s. deviation (all Cα atoms) for the Fab and 0.17 Å r.m.s. deviation (all Cα 
atoms) for the corresponding peptides (Supplementary Fig. 1b and Supplementary Fig. 3c).
Potency and Stability of Double-stapled MPER Epitopes
The small size of the MPER(671-683KKK) template, limited sites for installing staples, along 
with its rapid proteolysis (Supplementary Fig. 5) continued to render (i, i+4), (i, i+3) double 
stapling of the extended MPER peptide the most compelling design to maximize 
immunogenic surface, reinforce neutralization-competent structure, and ensure protease 
resistance. Applying R3-S5 (i, i+3) and S5-S5 (i, i+4) stapling, all five doubly constructs 
were successfully generated using the standard 4 h, room temperature metathesis conditions 
(Fig. 6a). Competitive 4E10 binding analysis demonstrated IC50s in the 130–600 nM range 
for double-stapled SAH-MPER(662-683) peptides. The best binder, SAH-
MPER(662-683)(D,q), nearly matched the binding activity of the corresponding single-stapled 
SAH-MPER(662-683)(q) construct (132 nM vs. 91 nM, respectively), in which the 4E10-
binding determinant (amino acids 671-683) is optimally stabilized by an i, i+3 staple at 
positions 678 and 681 (Fig. 6a).
To interrogate the relative protease resistance of double-stapled SAH-MPER constructs, 
peptides were subjected to chymotrypsin proteolysis and the time-dependent degradation of 
full-length SAH-MPER was monitored by HPLC-mass spectrometry (MS). Because the 
double-stapled SAH-MPER(662-683) constructs ionized poorly upon MS analysis, the library 
of constructs was also synthesized with C-terminal KKK tails, which increased ionization 
potential and facilitated detection of a greater breadth of fragment ions. As observed for the 
corresponding unmodified and q-stapled MPER(671-683KKK) constructs (Supplementary Fig. 
5), the unmodified and q-stapled full-length MPER(662-683KKK) peptides showed similar, 
rapid proteolysis profiles (Fig. 6b). In contrast, the introduction of double staples into the 
MPER(662-683KKK) sequence prolonged the proteolytic half-life by approximately 10- to 90-
fold compared to the corresponding unstapled construct (Fig. 6b). Of the eight chymotrypsin 
proteolysis sites observed for the unmodified peptide, the most stable double-stapled SAH-
MPERs eliminated the capacity of chymotrypsin to cleave all but one of them (Fig. 6c, 
Supplementary Fig. 6). Indeed, those chymotrypsin sites flanked by staples or located 
immediately adjacent to staples were completely shielded from proteolysis (Supplementary 
Fig. 6). Thus, at the expense of only a minor decrease in binding activity relative to the 
single-stapled SAH-MPER(662-683)(q) construct (1.4-fold), the double-stapled SAH-
MPER(662-683)(D,q) peptide, for example, achieves a 140-fold increase in chymotrypsin 
resistance. Although here we initially used 4E10 binding activity as a guide for candidate 
immunogen design, it is important to note that the variety of MPER-specific neutralizing 
antibodies identified to date recognize a spectrum of peptide templates and conformations. 
Thus, in addition to the 4E10-optimized double-stapled MPER peptides (Fig. 6a), constructs 
that do not engage 4E10 (Fig. 1b, 1c) could potentially represent a library of alternatively 
structured yet highly stable MPERs for immunization.
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Engagement of Double-stapled MPER Peptides by 10E8
The recent discovery of the 10E8 broadly neutralizing HIV-1 antibody10 provided a unique 
opportunity to explore the binding interactions between our double-stapled SAH-MPERs 
and a different anti-MPER Fab that recognizes a helically-structured MPER. We performed 
a 10E8 competitive ELISA binding assay analogous to that described above for 4E10, and 
again identified a series of compounds with nanomolar Fab-binding activity, including 
SAH-MPER(662-683)(A,q), SAH-MPER(662-683)(B,q) and SAH-MPER(662-683)(E,q) (Fig. 
7a). Notably, SAH-MPER(662-683)(C,q) and SAH-MPER(662-683)(D,q), which bound to 
4E10 Fab in the same nanomolar range as the other constructs (Fig. 6a), showed no binding 
activity to 10E8 Fab (Fig. 7a). These data are consistent with binding interactions between 
10E8 and residues that localize to the N-terminal portion of the MPER epitope10, such as 
S668 and L669, which are replaced by stapling amino acids in the (C,q)- and (D,q)-stapled 
MPER peptides. Although MPER residue W670 also contacts 10E8, replacement of this 
residue in SAH-MPER(662-683)(E,q) by a staple spanning the W666-W670 positions 
preserved high affinity 10E8 interaction. Thus, whereas 4E10 Fab sensed no differences in 
N-terminal staple position due to Fab engagement of the C-terminal portion of the MPER 
domain only, the 10E8 Fab was more discriminating in the upstream region that included N-
terminal residues of the MPER domain.
To determine if hydrocarbon double-stapling maintained the 10E8-bound conformation of 
the MPER domain, we determined the crystal structure of the 10E8 Fab in complex with 
SAH-MPER(662-683KKK)(B,q) (Fig. 7b). Crystals of the complex diffracted to 4.15 Å 
resolution (Table 2), and the structure was solved with molecular replacement and refined to 
Rcryst/Rfree of 22.1%/27.9%. Two complexes were observed in the asymmetric unit, with 
their corresponding peptides displaying a Cα root mean square deviation (RMSD) of 0.3 Å 
across gp41 residues 670-683. Electron density was observed around the C-terminal portion 
of the peptide, corresponding to gp41 residues S668-K683 for chain P (L669-K683 for chain 
C), and appeared to only partially cover the staple between residue positions 678 and 681 
(Supplementary Fig. 7a). The region upstream of chain P residue S668 (or chain C residue 
L669) that included the staple between positions 663 and 667 was disordered and could not 
be built. Nevertheless, the distinctive kink and adjacent N-terminal residues that distinguish 
10E8 from 4E10 interactions with the MPER domain are visualized and recapitulated in the 
10E8 Fab–SAH-MPER(662-683KKK)(B,q) complex (Fig. 7b).
Overall, the structure revealed that the staple between residue positions 678 and 681 largely 
reinforced the helical conformation of the C-terminal portion of the MPER peptide, as 
observed in the structure of 10E8 bound to the native gp41 MPER10. The highest degree of 
structural homology between the 10E8-bound stapled and unmodified peptides was 
observed between residues 670-683, yielding Cα and all-atom RMSDs of 0.6 and 1.8 Å, 
respectively (Supplementary Fig. 7b, Supplementary Table 2). Comparison of the contact 
interfaces between 10E8 and the stapled and unmodified gp41 MPER peptides also revealed 
a high degree of similarity, with many of the same residues mediating the interactions 
between them (Supplementary Table 3). An interfacial surface area of 633 Å2 was buried on 
the SAH-MPER(662-683KKK)(B,q) peptide, while 713 Å2 was buried on the antibody. The 
heavy chain of 10E8 accounted for a majority of the interactions with the double-stapled 
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peptide, representing 92% of the interface, consistent with the interactions observed between 
the 10E8 heavy chain and the native gp41 MPER peptide. Interactions between the light 
chain of 10E8 and the double-stapled peptide also closely mimicked the interactions 
observed with the native gp41 MPER peptide (Supplementary Table 3). Finally, structural 
superimposition of the 10E8 Fab–SAH-MPER(662-683KKK)(B,q) and 4E10 Fab–SAH-
MPER(671-683KKK)(q) complexes highlights the capacity of hydrocarbon-stapled antigens 
bearing the 671-683 motif to be differentially engaged by two distinct Fabs, each with potent 
and broadly neutralizing anti-HIV-1 activity (Fig. 7c)10,12.
DISCUSSION
The development of a safe and effective HIV-1 vaccine represents one of the most 
formidable scientific challenges of our time and remains the potential game-changer for 
curbing the global HIV-1 epidemic. The HIV-1 envelope glycoprotein represents the main 
target for a humoral immune response, yet the emergence of broadly neutralizing antibodies 
during natural infection only occurs after one or more years of infection due to a series of 
viral immune-evasion maneuvers50–52. Underlying the many “faces” of the HIV-1 envelope 
are critical functional intermediates whose structures, although shielded or only transiently 
exposed, provide a possible blueprint for antigen design. One such motif is the MPER 
domain, which is the physiologic target for a few broadly neutralizing antibodies. The 
structures of these antibody-MPER complexes, in addition to their non-neutralizing 
counterparts, have provided tremendous insight into exactly what three dimensional peptide-
encoded configuration may be required to guide an effective anti-HIV-1 immune 
response53,54. How to recapitulate and then stabilize the correct essential structure(s) in 
order to create a relatively homogeneous candidate immunogen capable of eliciting a safe, 
broad, and effective immune response has remained elusive.
The helical structure of the MPER domain when bound to distinct broadly neutralizing 
antibodies, such as 4E109 and the recently identified 10E810, suggests that structurally 
constrained peptides may provide a highly desirable template for candidate immunogen 
design. Seminal work in this area led both to the identification of key residues for 4E10 
engagement of a minimal essential helical MPER motif11 and the demonstration that peptide 
constraint through the installation of thioether, lactam, or triazole crosslinks, or helix-
promoting non-natural amino acids, could reinforce its structure and increase antibody 
binding affinity18,33,55. Structural analysis of the full-length MPER domain in a lipid 
context revealed a helix-kink-helix conformation, with α-helicity extending to the N-
terminus just after a bend induced at F67317. We viewed this bipartite structure as an ideal 
opportunity to increase the immunogenic surface compared to the minimal 4E10 binding 
epitope (671-683) by reinforcing both helical segments through installation of double 
constraints. We chose the all-hydrocarbon crosslink afforded by olefin metathesis of 
installed non-natural amino acids bearing olefin tethers56 due to the unique proteolytic 
stability conferred and the protease resistance of the hydrocarbon staple itself34. Guided by 
competitive 4E10 binding activity, we determined that antibody engagement of the C-
terminal region of the MPER domain is exquisitely sensitive to the site of staple insertion. 
Indeed, a single i, i+3 staple flanking the LW (679-680) sequence, previously shown to be 
critical for antibody interaction, yielded up to 60-fold enhancement in competitive 4E10 
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binding activity compared to the unmodified MPER peptide (Fig. 1c, 6a). The 10E8 
antibody engages both N- and C-terminal regions of the MPER domain and, in contrast to 
the 4E10 Fab, 10E8 was sensitive to the positioning of the N-terminal staple. These 
structure-activity relationship data highlight the capacity of staple scanning to uncover 
optimal sites for staple incorporation and antigenic structure stabilization.
Our i, i+3 stapling efforts and the synthetic challenges encountered in generating double-
stapled (i, i+4), (i, i+3) constructs using the traditional S5 non-natural residue, prompted us 
to develop optimized i, i+3 stapling chemistry that replaced S5 with R3 at the N-terminal 
stapling position. This intervention led to facile production of single- and double-stapled 
MPER peptides incorporating i, i+3 crosslinks, matching reaction conditions and yields of 
traditional i, i+4 stapling with S5 residues. Double-stapled constructs demonstrated 
nanomolar competitive binding affinity toward 4E10 and 10E8, with the best binder also 
manifesting 70-fold enhancement in proteolytic stability compared to the corresponding 
unstapled MPER peptide. This combination of structural stabilization and protease 
resistance afforded by hydrocarbon double-stapling may represent a highly desirable 
outcome for candidate immunogen development.
Structural analyses of SAH-MPER peptides in complex with 4E10 and 10E8 Fabs 
demonstrated the capacity of hydrocarbon stapling to recapitulate native antigenic peptide 
structures for two distinct broadly neutralizing anti-HIV-1 antibodies, preserving the critical 
peptide binding interface by positioning the i, i+3 crosslink on the noninteracting surface. 
The identification of an incorporated phosphate ion near the antigen-binding region of 4E10 
revealed a potential phospholipid binding site. Crystal structures of another broadly 
neutralizing HIV-1 antibody, 2F5, in complex with the MPER domain identified a putative 
anionic lipid binding site based on the incorporation of a sulfate ion at the base of the CDR 
H3 loop at high sulfate concentrations57. The binding mode and affinity by which diverse 
broadly neutralizing antibodies engage the lipid membrane may have important implications 
for candidate immunogen design and efficacy, and immunologic side effects38,39,43,57. By 
incorporating a phosphate tether into the SAH-MPER design, we effectively accessed the 
identified phosphate-binding region on 4E10. Indeed, as structured templates, hydrocarbon-
stapled peptides are amenable to facile derivatization to incorporate ancillary antibody-
binding determinants, and also reinforce unique architectures, such as the helix-kink-helix 
MPER motif. Thus, hydrocarbon stapling may serve as a useful addition to the arsenal of 
approaches aimed at fashioning just-the-right peptidic structure to elicit broadly neutralizing 
antibodies for HIV-1 and perhaps other vaccine targets.
ONLINE METHODS
Peptide Synthesis and Characterization
MPER and SAH-MPER peptides were synthesized, purified, quantified, and subjected to in 
vitro proteolysis testing as previously described34,58. Peptides were produced on an Apex 
396 (AAPPTEC) automated peptide synthesizer using Rink amide AM LL resin (EMD 
Biosciences, 0.2 mmol per g resin), at 20 μmol scale. To accomplish single i, i+3 stapling 
using S5 residues, prolonged reaction time at elevated temperature (10 h, refluxing 
dichloroethane) was required to match the yields of traditional i, i+4 stapling (4h, room 
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temperature). Protease reaction samples contained 5 μL peptide in DMSO (1 mM stock) and 
195 μL of buffer composed of 50 mM Tris-HCl pH 7.4, 2 mM CaCl2, and chymotrypsin (0.5 
ng per μL). Chymotryptic peptide fragments were analyzed by liquid chromatography–mass 
spectrometry (Agilent 1200).
Competitive 4E10 ELISA Binding Assay
A competitive enzyme-linked immunosorbent assay (ELISA) was employed to determine 
IC50s for SAH-MPER engagement of the 10E89 and 4E1010 antibodies. The following 
antibodies were obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH: HIV-1 gp41 Monoclonal Antibody 4E10 (catalog #10091) from Dr. H. 
Katinger and HIV-1 anti-gp41 Monoclonal Antibody 10E8 (catalog #12294) from Dr. M. 
Connors. Microwells were coated overnight at 4°C with 50 μl of 0.1 M NaHCO3 (pH 8.0) 
containing neutravidin (4 μg per ml). Plates were washed four times using an automated 
plate washer (Bio-Tek, ELX-50) with phosphate buffered saline containing 0.05% 
Tween-20 (PBST), and blocked with 4% bovine serum albumin (BSA) in PBST (filled to 
top of wells) for 45 min at 37 °C. Next, a mixture of biotin-PEG2-antigen 
(ELDKWASLWNWFNITNWLWYIK for the 4E10 assay or 
RRRNEQELLELDKWASLWNWFDITNWLWYIRRRR10 for the 10E8 assay) (20 nM), 
4E10 or 10e8 IgG (0.2 nM), and the competing SAH-MPER peptide (two-fold serial dilution 
from 1 μM to 1 nM across 10 columns) in PBST with 1% BSA (PBST-BSA), was incubated 
(125 μL total volume) in a separate 96-well plate at 37°C for 2 h. Controls included wells 
that lacked SAH-MPER competitor or 4E10 or 10E8 IgG. After washing the blocked 
neutravidin plate, 100 μL of the binding mixture was added for a 1 hour incubation at 37°C, 
followed by plate washing and the addition of a 1:5000 dilution of goat anti-human IgG for 
10E8 or IgG F(ab′)2 for 4E10 peroxidase conjugate in PBST-BSA. Following incubation at 
room temperature for 40 min, the wells were washed five times with PBST, and developed 
by adding 50 μl of tetramethylbenzidine (TMB) solution at room temperature. Wells 
containing the TMB solution were quenched after approximately 10 minutes by adding 50 μl 
of H2SO4 (2 M), and absorbance at 450 nm was read on a Spectramax microplate reader 
(Molecular Devices). Experiments were performed in triplicate and repeated at least twice. 
IC50 values for SAH-MPER competition were calculated by nonlinear regression analysis 
using Prism software (GraphPad).
4E10 Fab Purification and Crystallization of 4E10 Fab–SAH-MPER(671-683KKK) Complexes
4E10 IgG1(κ) expressed in recombinant Chinese Hamster Ovary cells (CHO) was purchased 
from Polymun Scientific Immunbiologische Forschung GmbH by the International AIDS 
Vaccine Initiative (IAVI). The 4E10 antigen-binding fragment Fab was obtained by papain 
digestion and purified to homogeneity as described previously12. The 4E10 Fab 
concentrated to ~10 mg per ml in 20 mM sodium acetate (pH 5.5) was mixed with the SAH-
MPER(671-683KKK)(q) (Ac-NWFNITNZLWXIK-KKK, where Z is R3 and X is S5) in a 1:4 
protein:peptide molar ratio and incubated overnight at 4°C prior to setting up crystallizations 
trials. The IAVI–JCSG–TSRI high-throughput CrystalMation system (Rigaku) was initially 
used to obtain crystallization conditions for the Fab–SAH-MPER(671-683KKK)(q) complex. 
Very thin long needles (5–10 μm in diameter) appeared in 2–3 weeks in drops containing 
4E10 Fab–SAH-MPER(671-683KKK)(q) and reservoir solution (50:50) equilibrated against 
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0.2 M sodium chloride, 0.1 M Na–K phosphate pH 6.2, and 50% polyethylene glycol 200. 
Micro and macro-seeding techniques using the reservoir solution were used to improve 
crystal size. The crystals were cryoprotected in mother liquor solutions containing ~60% 
polyethylene glycol 200.
The 4E10 Fab stock mixed with SAH-MPER(671-683KKK)(q)pSer (Ac-
NWFNITNZLWXI*KKK, where Z is R3, X is S5 and * is Dab-Gly-pSer) in a 1:5 molar 
ratio was incubated overnight at 4°C for complex formation. The initial screening trials lead 
to identification of several crystallization conditions that produced extremely small crystals. 
One of the conditions lacking PO4 ions was then used for further crystal optimization. 
Briefly, tiny needles crystals, grown by mixing equal amounts of 4E10 Fab–SAH-
MPER(671-683KKK)(q)pSer with reservoir solution (20% PEG 2,000, 0.1M Tris pH 7.0), 
were crushed using a Hampton Seeding bead and then seeded into a JCSG Top 96 screen 
(http://www.jcsg.org/top96). Long (ca. 200–300 μm), thick (ca. 60–70 μm) needle-like 
crystals grew from a mixture of equal amounts of complex and reservoir solution (0.2 M 
MgCl2, 0.1M MES pH 5.5, 40% PEG 400) and 20% of the aforementioned seeding stock in 
the final drop. The crystals were cryoprotected prior to data collection in mother liquor 
solution containing about 46% PEG 400.
4E10 Data collection, Structure Determination and Refinement
The X-ray diffraction data for 4E10 Fab–SAH-MPER(671-683KKK)(q) were collected at 110 
K on a MARMosaic 300 detector using synchrotron radiation (λ = 1.03317 Å) at the 
Advanced Photon Source (APS) 23ID-D beam line from crystals of ~40 μm in diameter that 
diffracted to approximately 2.9 Å resolution. To increase completeness in the high-
resolution shell, X-ray data sets from two crystals were indexed and scaled together using 
HKL200059. The diffraction data were indexed in space group P6122 as suggested by 
pointless60, xprep61 and phenix-Xtriage62 programs. Molecular replacement was performed 
with Phaser63, which led to one Fab–peptide complex per asymmetric unit with a rotation 
and translation function Z-scores of 10.6 and 42.8, respectively, and a log-likelihood gain of 
3,655. The initial positions of the models were optimized by rigid body refinement using 
Phenix64. Rebuilding of the model was performed in Coot65. Refinement was accomplished 
with Phenix using secondary structure restraints coupled with the refinement of individual 
atomic coordinates using gradient-driven (LBFGS) minimization and torsion angle 
simulated annealing, occupancy refinement, refinement of individual atomic displacement 
parameters and TLS refinement. Optimization of X-ray–stereochemistry and X-ray–ADP 
weights were also performed during refinement cycles. X-ray data quality and refinement 
statistics are included in Table 1. The Ramachandran statistics show 90.2% of the residues 
in the most favored regions, 5.8% in the additional allowed regions, and 4.0% in the 
disallowed regions. PyMOL (http://www.pymol.org/) was used to generate the 
crystallographic images.
The 4E10 Fab–SAH-MPER(671-683KKK)(q)pSer structure was solved from a single crystal 
X-ray diffraction data set (2.68 Å resolution) collected at 110 K on a MARMosaic 300 
detector at the APS 23ID-B beam line using a radiation wavelength of 1.03330 Å. Although 
the crystals were obtained from a different mother liquor composition than that of the 4E10 
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Fab–SAH-MPER(671-683KKK)(q) crystals, the auto-indexing suggested the same P6122 space 
group with similar unit cell values (Table 1). Molecular replacement performed using 
Phaser63 with only the Fab residues of the 4E10 Fab–SAH-MPER(671-683KKK)(q) complex 
resulted in one complex per asymmetric unit with a model rotation and translation function 
Z-scores of 13.3 and 68.2, respectively, and a log-likelihood gain of 4,403. Model building 
and refinement was performed as for the 4E10 Fab–SAH-MPER(671-68KKK)(q) complex 
except that cartesian-simulated annealing was used instead. The Ramachandran statistics 
show 93.8% of the residues in the most favored regions, 4.7% in the additional allowed 
regions, and 1.5% in the disallowed regions.
Expression and Purification of 10E8 and Generation of Fabs
Transient expression of the 10E8 antibody was undertaken in 293F cells or 293 Expi cells 
per the manufacturer’s instructions (Life Technologies) by co-transfection of equal amounts 
of the 10E8 heavy and light chain plasmids, as previously described66. 10E8 IgG was 
purified by capture with Protein A sepharose (Pierce) followed by elution in low pH (Pierce) 
with adjustment of eluate pH with Tris-Cl pH 8.0. The 10E8 Fab was prepared using 
endoproteinase Lys-C (Roche) digestion, as described66. The LysC protease was added at 
concentrations of 1:1,000 to 1:10,000 and the digestion undertaken at 37°C for 4–6 h. 
Digestion reactions were stopped with protease inhibitor tablets (Roche) and cleaved 
products were run over a Protein A column to segregate the Fc fragment. 10E8 Fab was then 
subjected to cation exchange (Mono S) and size-exclusion (S200) chromatography, followed 
by dialysis of peak fractions into 150 mM NaCl, 2.5 mM Tris, pH 7.5, 0.02% NaN3.
10E8 Crystallization, Structure Determination, and Structural Analysis
Purified 10E8 Fab in complex with SAH-MPER(662-683KKK)(B,q) was set up in 
crystallization screens using a Honeybee 963 robot. 576 initial conditions adapted from the 
commercially available Hampton (Hampton Research), Precipitant Synergy (Emerald 
Biosystems), and Wizard (Emerald Biosystems) crystallization screens were utilized to set 
up vapor diffusion sitting drop crystallizations at 20°C. Crystal trays were imaged with the 
use of a Rockimager (Formulatrix) and crystal hits were optimized manually. Crystals of the 
10E8 Fab in complex with SAH-MPER(662-683KKK)(B,q) were obtained in a crystallization 
condition comprised of 32% Isopropanol, 7.5% PEG 8000, 0.1 M Imidazole pH 6.5. 
Diffraction to 4.15 Å resolution was obtained in a cryoprotectant composed of mother liquor 
supplemented with 50% sucrose and excess peptide. Diffraction data were collected at SER 
CAT ID-22 beamline of the Advanced Photon Source (Argonne, IL) using a radiation 
wavelength of 1.0000 Å and processed using HKL-200059. The structure was solved with 
molecular replacement using Phaser63, with the high resolution structure of 10E8 Fab in 
complex with gp41 MPER peptide (PDB ID 4G6F) serving as the search model. Refinement 
was undertaken with Phenix67, utilizing PDB ID 4G6F as a reference model, with iterative 
model building in Coot68. Structures were validated with MolProbity69, and then analyzed 
using PISA for buried surface areas and residues70, and lsqkab for RMSD alignments (ccp4 
Package)71. The Ramachandran statistics show 96.56% of the residues in the most favored 
regions, 2.77% in the additional allowed regions, and 0.67% in the disallowed regions.
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Acknowledgments
We thank E. Smith for graphics assistance, D. Ekiert and E. Reinherz for insightful discussions, M. Connors 
(National Institute of Allergy and Infectious Diseases) for his generosity in providing us with a sample of 10E8 
antibody, and Y. Yang and P. Acharya for technical support. We are grateful to the National Institutes of Health 
(NIH) AIDS Reagent Program for providing us with 4E10 and 10E8 antibodies. This work was supported by the 
U.S. NIH Grant 1R01 AI084102 (L.D.W.), R01 AI36082 (I.A.W.), Scripps Center for HIV/AIDS Vaccine 
Immunology and Immunogen Discovery (CHAVI-ID) UM1 AI100663 (I.A.W.), the International AIDS Vaccine 
Initiative (IAVI), Neutralizing Antibody Center, IAVI Collaboration for AIDS Vaccine Discovery, the Bill and 
Melinda Gates Foundation, and the Intramural Research Program of the Vaccine Research Center, National 
Institute of Allergy and Infectious Diseases (NIAID), NIH. Use of the 23-ID sector at Advanced Photon Source was 
supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract 
No. DE-AC02-06CH11357.
References
1. Fauci AS, et al. HIV vaccine research: the way forward. Science. 2008; 321:530–2. [PubMed: 
18653883] 
2. Rits-Volloch S, Frey G, Harrison SC, Chen B. Restraining the conformation of HIV-1 gp120 by 
removing a flexible loop. Embo J. 2006; 25:5026–35. [PubMed: 17006538] 
3. Matthews TJ, et al. Interaction between the human T-cell lymphotropic virus type IIIB envelope 
glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. 
Proc Natl Acad Sci U S A. 1987; 84:5424–8. [PubMed: 3037551] 
4. Xiao L, et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of 
phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain 
that predicts CCR-5 usage. Virology. 1998; 240:83–92. [PubMed: 9448692] 
5. Buzon V, et al. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane 
proximal external regions. PLoS Pathog. 2010; 6:e1000880. [PubMed: 20463810] 
6. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. 
Cell. 1997; 89:263–73. [PubMed: 9108481] 
7. Muster T, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. 
J Virol. 1993; 67:6642–7. [PubMed: 7692082] 
8. Zwick MB, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region 
of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001; 75:10892–10905. 
[PubMed: 11602729] 
9. Stiegler G, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel 
epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2001; 
17:1757–1765. [PubMed: 11788027] 
10. Huang J, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. 
Nature. 2012; 491:406–12. [PubMed: 23151583] 
11. Brunel FM, et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human 
immunodeficiency virus type 1 antibody. J Virol. 2006; 80:1680–7. [PubMed: 16439525] 
12. Cardoso RM, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation 
of a highly conserved fusion-associated motif in gp41. Immunity. 2005; 22:163–73. [PubMed: 
15723805] 
13. Coutant J, et al. Both lipid environment and pH are critical for determining physiological solution 
structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. Faseb J. 2008; 
22:4338–51. [PubMed: 18776068] 
14. Huarte N, Lorizate M, Kunert R, Nieva JL. Lipid modulation of membrane-bound epitope 
recognition and blocking by HIV-1 neutralizing antibodies. FEBS Lett. 2008; 582:3798–804. 
[PubMed: 18930052] 
Bird et al. Page 15
Nat Struct Mol Biol. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
15. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the 
human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and 
target for vaccine design. Microbiol Mol Biol Rev. 2008; 72:54–84. [PubMed: 18322034] 
16. Ofek G, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 
antibody 2F5 in complex with its gp41 epitope. J Virol. 2004; 78:10724–37. [PubMed: 15367639] 
17. Sun ZY, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 
ectodomain region on the viral membrane. Immunity. 2008; 28:52–63. [PubMed: 18191596] 
18. Cardoso RM, et al. Structural basis of enhanced binding of extended and helically constrained 
peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol. 2007; 365:1533–
44. [PubMed: 17125793] 
19. Penn-Nicholson A, et al. Assessment of antibody responses against gp41 in HIV-1-infected 
patients using soluble gp41 fusion proteins and peptides derived from M group consensus 
envelope. Virology. 2008; 372:442–56. [PubMed: 18068750] 
20. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR. Aromatic residues at the edge of 
the antibody combining site facilitate viral glycoprotein recognition through membrane 
interactions. Proc Natl Acad Sci U S A. 2010; 107:1529–34. [PubMed: 20080706] 
21. Ofek G, et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci 
U S A. 2010; 107:17880–7. [PubMed: 20876137] 
22. Guenaga J, et al. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses 
to the HIV-1 gp41 2F5 neutralization determinant. PLoS One. 2011; 6:e16074. [PubMed: 
21297864] 
23. Correia BE, et al. Computational design of epitope-scaffolds allows induction of antibodies 
specific for a poorly immunogenic HIV vaccine epitope. Structure. 2010; 18:1116–26. [PubMed: 
20826338] 
24. Correia BE, et al. Computational protein design using flexible backbone remodeling and 
resurfacing: case studies in structure-based antigen design. J Mol Biol. 2011; 405:284–97. 
[PubMed: 20969873] 
25. Stanfield RL, et al. Structure-based design of a protein immunogen that displays an HIV-1 gp41 
neutralizing epitope. J Mol Biol. 2011; 414:460–76. [PubMed: 22033480] 
26. Yi G, et al. Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing 
responses. PLoS One. 2013; 8:e72205. [PubMed: 24039745] 
27. Dawood R, et al. Generation of HIV-1 potent and broad neutralizing antibodies by immunization 
with postfusion HR1/HR2 complex. Aids. 2013; 27:717–30. [PubMed: 23719346] 
28. Wahome N, et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling 
protein nanoparticles as a potential HIV vaccine. Chem Biol Drug Des. 2012; 80:349–57. 
[PubMed: 22650354] 
29. Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit 
vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines. 2010; 9:157–73. 
[PubMed: 20109027] 
30. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in 
vaccine design. Nat Rev Drug Discov. 2007; 6:404–14. [PubMed: 17473845] 
31. Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple long or 
short alone or in combination? Cancer J. 2011; 17:343–50. [PubMed: 21952285] 
32. Ho J, et al. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope 
result in increased antigenicity but not neutralizing response. Vaccine. 2005; 23:1559–73. 
[PubMed: 15694508] 
33. Ingale S, Gach JS, Zwick MB, Dawson PE. Synthesis and analysis of the membrane proximal 
external region epitopes of HIV-1. J Pept Sci. 2010; 16:716–22. [PubMed: 21104968] 
34. Bird GH, et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy 
peptide therapeutic. Proc Natl Acad Sci U S A. 2010; 107:14093–14098. [PubMed: 20660316] 
35. Leaman DP, Zwick MB. Increased functional stability and homogeneity of viral envelope spikes 
through directed evolution. PLoS Pathog. 2013; 9:e1003184. [PubMed: 23468626] 
36. Zolla-Pazner S. A critical question for HIV vaccine development: which antibodies to induce? 
Science. 2014; 345:167–8. [PubMed: 25013066] 
Bird et al. Page 16
Nat Struct Mol Biol. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
37. Scherer EM, Zwick MB, Teyton L, Burton DR. Difficulties in eliciting broadly neutralizing anti-
HIV antibodies are not explained by cardiolipin autoreactivity. Aids. 2007; 21:2131–2139. 
[PubMed: 18090039] 
38. Matyas GR, et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide 
simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. Aids. 2009; 23:2069–
2077. [PubMed: 19710597] 
39. Matyas GR, Beck Z, Karasawas N, Alving CR. Lipid binding properties of 4E10, 2175, and 
WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta. 2009; 1788:660–
665. [PubMed: 19100711] 
40. Maeso R, et al. Interaction of Anti-HIV Type 1 Antibody 2F5 with Phospholipid Bilayers and Its 
Relevance for the Mechanism of Virus Neutralization. AIDS Res Hum Retroviruses. 2011; 
27:863–876. [PubMed: 21142698] 
41. Haynes BF, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 
antibodies. Science. 2005; 308:1906–8. [PubMed: 15860590] 
42. Alam SM, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly 
neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 
membrane proximal envelope epitopes. J Immunol. 2007; 178:4424–35. [PubMed: 17372000] 
43. Chen J, et al. Mechanism of HIV-1 Neutralization by Antibodies Targeting a Membrane-Proximal 
Region of gp41. J Virol. 2014; 88:1249–58. [PubMed: 24227838] 
44. Bernal F, et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 
2010; 18:411–22. [PubMed: 21075307] 
45. LaBelle JL, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J 
Clin Invest. 2012; 122:2018–31. [PubMed: 22622039] 
46. Takada K, et al. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt 
signaling. Sci Transl Med. 2012; 4:148ra117.
47. Walensky LD, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 
2004; 305:1466–70. [PubMed: 15353804] 
48. Kim YW, Kutchukian PS, Verdine GL. Introduction of all-hydrocarbon i,i+3 staples into alpha-
helices via ring-closing olefin metathesis. Org Lett. 2010; 12:3046–9. [PubMed: 20527740] 
49. Finton KA, et al. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) 
hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog. 2013; 9:e1003639. [PubMed: 
24086134] 
50. Hraber P, et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 
infection. Aids. 2014; 28:163–9. [PubMed: 24361678] 
51. Liao HX, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 
2013; 496:469–76. [PubMed: 23552890] 
52. Locci M, et al. Human circulating PD-(+)1CXCR3(−)CXCR5(+) memory Tfh cells are highly 
functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013; 
39:758–69. [PubMed: 24035365] 
53. Frey G, et al. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and 
non-neutralizing antibodies. Nat Struct Mol Biol. 2010; 17:1486–91. [PubMed: 21076402] 
54. Frey G, et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing 
antibodies. Proc Natl Acad Sci U S A. 2008; 105:3739–44. [PubMed: 18322015] 
55. Ingale S, Dawson PE. On resin side-chain cyclization of complex peptides using CuAAC. Org 
Lett. 2011; 13:2822–5. [PubMed: 21553819] 
56. Schafmeister C, Po J, Verdine G. An all-hydrocarbon cross-linking system for enhancing the 
helicity and metabolic stability of peptides. J Am Chem Soc. 2000; 122:5891–5892.
57. Julien JP, Bryson S, Nieva JL, Pai EF. Structural details of HIV-1 recognition by the broadly 
neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, 
and anion-binding site. J Mol Biol. 2008; 384:377–92. [PubMed: 18824005] 
58. Bird GH, Bernal F, Pitter K, Walensky LD. Synthesis and biophysical characterization of 
stabilized alpha-helices of BCL-2 domains. Methods Enzymol. 2008; 446:369–86. [PubMed: 
18603134] 
Bird et al. Page 17
Nat Struct Mol Biol. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
59. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. 
Macromol Crystallogr A. 1997; 276:307–326.
60. Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr. 2006; 62:72–
82. [PubMed: 16369096] 
61. Sheldrick GM. A short history of SHELX. Acta Crystallogr A. 2008; 64:112–122. [PubMed: 
18156677] 
62. Zwart PH, Grosse-Kunsteleve RW, Adams PD. Characterization of X-ray data sets. CCP4 
Newsletter. 2005; 42:1–10.
63. McCoy AJ, et al. Phaser crystallographic software. J Appl Crystallogr. 2007; 40:658–674. 
[PubMed: 19461840] 
64. Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure 
solution. Acta Crystallogr D Biol Crystallogr. 2010; 66:213–221. [PubMed: 20124702] 
65. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr 
D Biol Crystallogr. 2010; 66:486–501. [PubMed: 20383002] 
66. Huang J, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. 
Nature. 2012; 491:406–412. [PubMed: 23151583] 
67. Adams PD, et al. PHENIX: building new software for automated crystallographic structure 
determination. Acta Crystallogr D Biol Crystallogr. 2002; 58:1948–1954. [PubMed: 12393927] 
68. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol 
Crystallogr. 2004; 60:2126–2132. [PubMed: 15572765] 
69. Davis IW, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic 
acids. Nucleic Acids Res. 2007; 35:W375–W383. [PubMed: 17452350] 
70. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 
2007; 372:774–797. [PubMed: 17681537] 
71. Winn MD, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol 
Crystallogr. 2011; 67:235–42. [PubMed: 21460441] 
Bird et al. Page 18
Nat Struct Mol Biol. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Design and 4E10 Binding Activity of Hydrocarbon-Stapled MPER Peptides
(a) Structure of the extended HIV-1 MPER domain in the lipid environment17 (left) and 
when bound to the broadly neutralizing 10E8 antibody (4G6F)10 (right). (b) Single i, i+4 
hydrocarbon staples were sequentially inserted into the N-terminal half of the MPER 
sequence and the resultant SAH-MPER(662-683) constructs (A–F) subjected to competitive 
4E10 ELISA assay. The N-terminal helical wheel depicts staple placement along the MPER 
sequence. (c) Single i, i+4 and i, i+3 hydrocarbon staples were sequentially inserted into the 
C-terminal half of the MPER sequence and the binding activity of the resultant SAH-
MPER(662-683) constructs (G–S) evaluated by competitive 4E10 ELISA assay. The C-
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terminal helical wheel depicts staple placement along the MPER sequence. Error bars, s.e.m. 
(n = 3 binding assay replicates).
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Figure 2. Chemical Optimization of i, i+3 Hydrocarbon Stapling
(a) Design and synthesis of SAH-MPER(671-683KKK)(Q) using S5 olefinic tethers to generate 
the i, i+3 staple. HPLC traces of starting material (grey) and product (yellow) demonstrate 
the low yield of reaction product even after prolonged incubation at reflux conditions. (b) 
Design and synthesis of SAH-MPER(671-683KKK)(q), in which the N-terminal S5 residue 
was replaced with R3, leading to efficient i, i+3 olefin metathesis using standard reaction 
conditions. HPLC traces of starting material (grey) and product (blue) demonstrate the high 
yield of reaction product. (c) Competitive 4E10 binding activity of SAH-
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MPER(671-683KKK)(q) compared to the corresponding unstapled peptide. Error bars, s.e.m. 
(n = 3 binding assay replicates). Fmoc, Fluorenylmethoxycarbonyl
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Figure 3. Structural Analysis of the 4E10 Fab–SAH-MPER(671-683KKK)(q) Complex
(a) Crystal structure of SAH-MPER(671-683KKK)(q) (shown as a blue ribbon and gray 
transparent van der Waals surface) bound to 4E10 Fab at 2.9 Å resolution. (b) 2Fo-Fc 
electron density map (1σ level) of the antibody-bound SAH-MPER(671-683KKK)(q) peptide. 
(c) Superimposition of the native (green, 2FX7)18 and i, i+3-stapled (gray) 
MPER(671-683KKK) peptides highlights the similarity of antibody-bound structures, aside 
from the appended C-terminal lysines and the incorporated staple. Z and X represent R3 and 
S5, respectively.
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Figure 4. Identification of a Candidate Phospholipid Binding Site at the 4E10 Interface
(a) Incorporation of a phosphate ion from the mother liquor into the crystal structure of the 
4E10 Fab–SAH-MPER(671-683KKK)(q) complex. The presence of a phosphate binding site in 
the CDR-H1 loop region of 4E10 is consistent with its binding mode at the membrane 
surface. The transmembrane region (replaced here by three lysines for solubility purposes) 
that would be membrane embedded in the virion is indicated with an arrow. (b) 2Fo-Fc 
electron density map (1σ level) of the phosphate binding site located between residues 
S28(H) and S30(H) of the CDR-H1 loop. (c) Superimposition of the phosphate-incorporated 
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site of the 4E10 Fab–SAH-MPER(671-683KKK)(q) structure (gray) with that region of the 
4E10 Fab–native MPER(671-683KKK) peptide complex (green; PDB entry 2FX718).
Bird et al. Page 25
Nat Struct Mol Biol. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. A Phosphate Tether Incorporated into SAH-MPER(671-683KKK)(q) Engages the 
Putative Lipid Binding Site
(a) Position 683 of SAH-MPER(671-683KKK)(q) was derivatized with a Dab-Gly-pSer tether 
(brown) to span the measured 5.5 Å between the primary amine of Lys683 and the 
phosphate observed at the 4E10 Fab–SAH-MPER(671-683KKK)(q) interface. (b) Crystal 
structure of the SAH-MPER(671-683KKK)(q)pSer complex (shown as a green ribbon and 
wheat transparent Van der Waals surface) bound to 4E10 at 2.68 Å resolution. (c) The 2Fo-
Fc electron density map (1σ level) of the antibody-bound SAH-MPER(671-683KKK)(q)pSer 
construct.
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Figure 6. Synthesis, Protease Stability, and 4E10 Binding Activity of Double-stapled SAH-MPER 
Peptides
(a) A series of double-stapled SAH-MPER(662-683) peptides were tested for 4E10 binding 
activity by competitive ELISA assay. (b) Comparative chymotrypsin resistance of SAH-
MPER(662-683) peptides, as monitored by LC/MS over time. Proteolysis was performed with 
SAH-MPER constructs bearing C-terminal KKKs to optimize peptide ionization for MS 
analysis. Error bars, s.e.m. (n = 3 proteolysis reaction replicates). (c) MS-based peptide 
fragment analysis identified the sites of chymotrypsin proteolysis. Whereas chymotrypsin 
sites (yellow arrowheads) located within or adjacent to the installed staples (red X-X, Z-X 
pairs) were completely protected from proteolysis, the cleavage kinetics for intervening 
site(s) was progressively slowed (A,q<B,q<C,q<D,q<E,q) by the induced structure of the 
approaching N-terminal staple (red X-X pairs).
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Figure 7. 10E8 Binding Activity of Double-stapled SAH-MPER Peptides and Structural Analysis 
of the 10E8 Fab–SAH-MPER(662-683KKK)(B,q) Complex
(a) Comparative binding activity of double-stapled SAH-MPER(662-683) peptides for 10E8, 
as measured by competitive ELISA assay against the unmodified 10E8 ligand 
RRRNEQELLELDKWASLWNWFDITNWLWYIRRRR10. (b) Crystal structure of SAH-
MPER(662-683KKK)(B,q) (shown as a cyan ribbon with stick residues) bound to 10E8 Fab at 
4.15 Å resolution. (c) Superimposition of the 4E10 Fab–SAH-MPER(671-683KKK)(q) and 
10E8 Fab–SAH-MPER(662-683KKK)(B,q) complexes highlights how the two anti-HIV Fabs 
differentially engage the stapled MPER antigens.
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Table 1
Data collection and refinement statistics for the 4E10 Fab–SAH-MPER(671-683KKK)(q) and the 4E10 Fab–
SAH-MPER(671-683KKK)(q)pSer complexes
4E10 Fab SAH-MPER(671-683KKK)(q) 4E10 Fab SAH-MPER(671-683KKK)(q)pSer
Data collection
Space group P6122 P6122
Cell dimensions
 a, b, c (Å) 226.10, 226.10, 41.82 226.51, 226.51, 42.33
 α, β, γ (°) 90.00, 90.00, 120.00 90.00, 90.00, 120.00
Resolution (Å) 48.95-2.91 (2.96-2.91) * 49.04-2.68 (2.75-2.68) *
Rmerge (%)** 18.2 (66.6) 9.3 (59.7)
Rpim 4.2 (22.7) 2.1 (13.4)
I/σI 16.4 (3.1) 28.0 (5.6)
Completeness (%) 95.6 (70.4) 99.9 (100)
Redundancy 21.9 (7.8) 20.7 (20.3)
Refinement
Resolution (Å) 48.95-2.91 49.04-2.68
No. reflections 13,737 (501) 18,583 (1,335)
Rwork/Rfree (%) 21.0/26.8 17.0/22.2
No. atoms
 Protein 3,353 3,344
 Peptide 150 162
 PO4 ion 5 0
 TFA 14 0
 Water 29 98
B factors (Å2)
 Wilson plot 63.8 52.0
 Protein 70.7 51.2
 Peptide 81.1 59.8
 Staple 75.0 48.5
 PO4 ion 110.5 -----
 Dab-Gly-pSer ----- 105.6
 Water 50.5 46.7
r.m.s. deviations
 Bond lengths (Å) 0.006 0.010
 Bond angles (°) 0.79 1.34
*Values in parentheses are for highest-resolution shell.
**
Data sets from two crystals were merged together for 4E10 Fab–SAH-MPER(671-683KKK)(q) complex. A full data set was collected on one 
crystal for 4E10 Fab–SAH-MPER(671-683KKK)(q)pSer complex.
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Table 2
Data collection and refinement statistics for the 10E8 Fab–SAH-MPER(662-683KKK)(B,q) complex
10E8 Fab SAH-MPER(662-683KKK)(B,q)
Data collection
Space group P 21 21 21
Cell dimensions
 a, b, c (Å) 68.6 126.3 129.9
 α, β, γ (°) 90, 90, 90
Resolution (Å) 50-4.15 (4.25-4.15) *
Rmerge (%)** 30.2 (56.4)
I/σI 5.6 (2.9)
Completeness (%) 95.1 (83.3)
Redundancy 6.4 (5.1)
Refinement
Resolution (Å) 40.05-4.20 (4.35 - 4.20)
No. reflections 8120 (624)
Rwork/Rfree (%) 24.32/27.53
No. atoms
 Protein 7025
 Peptide 0
 Water 0
B factors (Å2)
 Protein 76.90
r.m.s. deviations
 Bond lengths (Å) 0.002
 Bond angles (°) 0.60
*Values in parentheses are for highest-resolution shell.
**A full data set was collected on one crystal.
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